Balaxi (BALAXI) | Stock Overview & Key Data
Balaxi Performance Comparison
Stock Range
Today's Range
Low: ₹44.53
High: ₹45.34
on October 3, 2025
52 Week Range
Low: ₹42.17
High: ₹105.38
on September 29, 2025
on October 3, 2024
All-Time High: ₹216.04 on October 12, 2020
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR2.5B
EPS
3.42
P/E Ratio (TTM)
13.02
Forward P/E
N/A
P/B Ratio
1.06
PEG Ratio
-0.14
Div. Yield
N/A
ROE
-1.24%
Beta
0.594
Debt to Equity
9.64
Financial Highlights
Profitability
Gross Margin
44.08%
Operating Margin
21.39%
Profit Margin
-0.99%
Returns and Earnings
Return on Assets (TTM)
11.20%
Return on Equity (TTM)
-1.24%
EBITDA
INR276.3M
Net Income (TTM)
INR-23.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR43.71
Quarterly Revenue Growth (YoY)
-25.80%
Quarterly Earnings Growth (YoY)
35.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Balaxi BALAXI | 2.46B Small-cap | 4.03% | -2.67% | -8.14% | -33.99% | -37.65% | -54.92% | -62.62% | -76.27% |
| Biocon BIOCON | 470.24B Large-cap | 3.94% | -2.57% | -5.93% | 1.88% | -4.49% | 1.70% | 24.54% | -22.05% |
| OneSource Specialty ONESOURCE | 212.56B Large-cap | 0.90% | -4.90% | -9.68% | 14.74% | 5.61% | 5.61% | 5.61% | 5.61% |
| Zota Health Care ZOTA | 45.32B Small-cap | -4.00% | 16.56% | 44.43% | 72.88% | 76.58% | 137.77% | 382.52% | 863.38% |
| Dishman Carbogen DCAL | 45.33B Small-cap | 1.33% | 6.52% | 11.35% | 26.46% | -0.11% | 62.68% | 168.99% | 66.89% |
| Panacea Biotec PANACEABIO | 25.45B Small-cap | -0.04% | -2.22% | -4.62% | -10.01% | -7.42% | 32.45% | 205.48% | 115.98% |
Ownership & Short Interest
Insider Ownership
N/A
Institutional Ownership
N/A
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
90K
Average 90-Day Volume
112K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BALAXI's 52-week high and low?
- In the last 52 weeks, Balaxi reached a high of ₹105.38 (on October 3, 2024) and a low of ₹42.17 (on September 29, 2025).
- What is the market cap and P/E ratio for BALAXI?
- Curious about Balaxi's size and valuation? Its market capitalization stands at 2.46B. When it comes to valuation, the P/E ratio (trailing twelve months) is 13.02, and the forward P/E (looking ahead) is N/A.
- Does BALAXI pay dividends? If so, what's the yield?
- As for dividends, Balaxi isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Balaxi's main competitors or similar companies to consider before investing?
When looking at Balaxi, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON470.24B Healthcare Biotechnology 1.70% 24.54% OneSource Specialty
ONESOURCE212.56B Healthcare Biotechnology 5.61% 5.61% Zota Health Care
ZOTA45.32B Healthcare Biotechnology 137.77% 382.52% Dishman Carbogen
DCAL45.33B Healthcare Biotechnology 62.68% 168.99% Panacea Biotec
PANACEABIO25.45B Healthcare Biotechnology 32.45% 205.48% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Balaxi Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Balaxi's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -1.24%, the Debt to Equity ratio from the most recent quarter is 9.64, and its Gross Profit Margin stands at 44.08%.
- What is the recent revenue and earnings growth for BALAXI?
- Looking at Balaxi's growth, its revenue over the trailing twelve months (TTM) was INR2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -25.80%, and quarterly earnings saw a YoY growth of 35.00%.
- How much of BALAXI stock is held by insiders and institutions?
- Wondering who owns Balaxi stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.